Background/aims: Self-expanding metallic stents (SEMS) are an alternative to emergency surgery (ES) for malignant colorectal obstruction. This study aimed to compare surgical outcomes between SEMS as a bridge to surgery (BTS) and ES in patients with malignant colorectal obstruction.
Methods: A comprehensive database search was conducted until October 2023 to compare outcomes between SEMS as a BTS and ES. A subgroup analysis of results by malignancy site was performed.
Results: We analyzed 57 studies, including 7,223 patients over a mean duration of 35.4 months. SEMS as a BTS showed clinical and technical success rates of 88.0% (95% confidence interval [CI], 86.1%-90.1%; I2=68%) and 91.6% (95% CI, 89.7%-93.7%; I2=66%), respectively. SEMS as a BTS revealed reduced postoperative adverse events (odds ratio [OR], 0.51; 95% CI, 0.41-0.63; I2=70%; p<0.001) and 30-day mortality (OR, 0.52; 95% CI, 0.37-0.72; I2=10%; p<0.001) compared to ES. Subgroup analysis showed postoperative mortality of 5% and 1.5% for left- and right-sided malignancies, respectively. Adverse events were 15% and 33% for the right and left colon, respectively.
Conclusions: SEMS as a BTS demonstrated higher success rates, fewer postoperative adverse events, and a reduced 30-day mortality rate than ES, supporting its use as the preferred initial intervention for right- and left-sided obstructions and indicating broader clinical adoption.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5946/ce.2024.120 | DOI Listing |
Keio J Med
March 2025
Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.
Hereditary breast and ovarian cancer syndrome (HBOC) is traditionally associated with mutations in the BRCA1 and BRCA2 genes, predominantly impacting breast, ovarian, pancreatic, and prostate cancers. However, recent research suggests that these mutations may also predispose carriers to a broader spectrum of malignancies, including biliary tract, cervical, colorectal, endometrial, esophageal, and gastric cancers. This review presents findings from extensive datasets, including a significant study from a nationwide Japanese biobank that examined cancer risks in 63,828 patients and 37,086 controls.
View Article and Find Full Text PDFGan To Kagaku Ryoho
February 2025
Dept. of Surgery, Tokyo Women's Medical University Adachi Medical Center.
We investigated the short-term outcomes of robot-assisted surgery for rectal cancer in our department. Among 98 cases of colorectal cancer who underwent robot-assisted surgery between October 2019 and December 2023, 91 cases of rectal cancer surgery using the da Vinci X surgical system® were included, and clinicopathological and surgical outcomes were examined. The patients included 58 males and 33 females, with a median age of 71 years.
View Article and Find Full Text PDFGan To Kagaku Ryoho
February 2025
Dept. of Surgery, Kinki Central Hospital.
A male in his 80s with a history of multiple colorectal cancer resections underwent an upper gastrointestinal endoscopy for anemia investigation, which revealed a non-ampullary duodenal carcinoma. Due to insufficient surgical tolerance for pancreaticoduodenectomy, pharmacotherapy was considered. With informed consent, an MSI test was conducted, showing MSI-high, leading to the initiation of pembrolizumab treatment.
View Article and Find Full Text PDFGan To Kagaku Ryoho
February 2025
Dept. of Gastroenterological Surgery, Akita City Hospital.
An 81-year-old man underwent a partial laparoscopic hepatectomy for tumors in the S7 segment of the liver and was diagnosed with moderately to poorly differentiated hepatocellular carcinoma(HCC). Two years and 10 months later, MRI identified a 10 mm tumor in the S8 segment of the liver, indicative of highly differentiated HCC. Colorectal endoscopy subsequently revealed a submucosal tumor in the transverse colon, with biopsy findings showing features similar to the previous HCC.
View Article and Find Full Text PDFCancer
March 2025
Department of Oncology, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan, USA.
Background: Prior studies of participants with breast and other obesity-associated cancers in the Women's Health Initiative (WHI) showed worse mortality and cardiovascular disease (CVD) outcomes for individuals with a higher number of cardiometabolic risk factors at study entry. The purpose of this analysis is to compare the relationship between cardiometabolic abnormalities and mortality among women with and without cancer in the WHI.
Methods: Women with one of five early-stage obesity-associated cancers (breast, colorectal, endometrial, ovarian, and non-Hodgkin lymphoma) and controls without any new or prior history of cancer were selected from the WHI-Life and Longevity after Cancer ancillary study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!